TradeFlare's AI research teams analysed EWTX on 17 market nights between April 27, 2026 and August 31, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| August 31, 2026 | BUY | $42.76 | $47.04 / $36.35 | +4.9% | -6.2% | The setup is based on a technical pullback within a fundamentally bullish narrative, suggesting a medium-term recovery. |
| July 16, 2026 | BUY | $40.83 | $47.49 / $34.69 | +2.9% | +13.1% | The bullish fundamental and sentiment outlook, coupled with a neutral technical setup, suggests a breakout is likely in the coming weeks. |
| July 15, 2026 | BUY | $39.73 | — / — | -6.1% | +6.7% | The current market regime is neutral, and while EWTX has strong fundamental and sentiment scores, the technicals are bearish, and the risk score is high, preventing a buy recommendation. |
| July 14, 2026 | BUY | $41.27 | $48.49 / $35.08 | -0.4% | +11.5% | The fundamental and sentiment catalysts suggest a medium-term upward trend. |
| July 13, 2026 | BUY | $45.41 | $53.00 / $38.59 | -6.0% | +8.0% | The bullish fundamental and sentiment outlook, coupled with positive technicals, suggests a multi-week upward trend is likely. |
| July 10, 2026 | BUY | $48.35 | — / — | -12.4% | -4.2% | The market regime is neutral, and while EWTX has some positive sentiment, the technicals and fundamentals are neutral, and the risk score is high. |
| July 2, 2026 | BUY | $39.15 | — / — | +14.8% | -2.9% | The current market regime and stock-specific technicals do not support a new entry. |
| July 1, 2026 | BUY | $40.63 | $44.70 / $34.53 | +23.5% | +5.0% | The bullish fundamental and sentiment outlook, coupled with the technical setup near resistance, suggests a short-to-medium term upward move is plausible. |
| June 30, 2026 | BUY | $40.92 | — / — | +14.0% | -2.2% | Positive Phase 2 HCM trial data for EDG-7500. |
| June 25, 2026 | BUY | $42.30 | $51.00 / $35.96 | -5.1% | -2.0% | The technical setup suggests an imminent breakout, and the fundamental catalysts are expected to play out over the medium term. |
| June 24, 2026 | BUY | $38.83 | $43.69 / $32.29 | -7.5% | -7.1% | The setup requires time for the technical momentum to develop and for fundamental catalysts to play out. |
| June 23, 2026 | HOLD | $36.50 | — / — | +4.6% | -1.3% | Positive clinical trial data for drug candidates targeting unmet medical needs. |
| June 22, 2026 | HOLD | $36.81 | — / — | +12.1% | +8.4% | Positive clinical trial data for EDG-7500. |
| June 19, 2026 | BUY | $36.81 | — / — | +12.1% | +8.4% | Successful progression of EWTX's drug pipeline through clinical trials. |
| June 18, 2026 | HOLD | $34.82 | — / — | +12.6% | +5.4% | Positive trial results for EDG-7500 have generated some optimism. |
| April 28, 2026 | BUY | $30.64 | — / — | +22.6% | +8.2% | Positive clinical trial data for sevasemten. |
| April 27, 2026 | SELL | $31.58 | — / — | +2.6% | +9.5% | Positive clinical trial data for drug candidates. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.